Krystal Biotech, Inc. (NASDAQ:KRYS) Position Increased by Integral Health Asset Management LLC

Integral Health Asset Management LLC raised its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 6.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 85,000 shares of the company’s stock after buying an additional 5,000 shares during the period. Krystal Biotech comprises approximately 1.5% of Integral Health Asset Management LLC’s investment portfolio, making the stock its 20th biggest position. Integral Health Asset Management LLC owned approximately 0.30% of Krystal Biotech worth $15,609,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. EFG Asset Management North America Corp. boosted its holdings in Krystal Biotech by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock worth $2,308,000 after buying an additional 60 shares in the last quarter. GAMMA Investing LLC boosted its stake in Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after purchasing an additional 93 shares during the period. Nisa Investment Advisors LLC boosted its stake in Krystal Biotech by 11.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock worth $173,000 after purchasing an additional 94 shares during the period. Arizona State Retirement System boosted its stake in Krystal Biotech by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock worth $945,000 after purchasing an additional 108 shares during the period. Finally, Fiera Capital Corp boosted its stake in Krystal Biotech by 0.8% in the 2nd quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock worth $2,976,000 after purchasing an additional 130 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 14.10% of the stock is currently owned by company insiders.

Krystal Biotech Trading Down 0.2 %

Krystal Biotech stock opened at $184.17 on Monday. The company has a market capitalization of $5.26 billion, a P/E ratio of 98.49 and a beta of 0.82. The firm’s fifty day simple moving average is $195.14 and its 200-day simple moving average is $179.47. Krystal Biotech, Inc. has a 1-year low of $93.95 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.03. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The business had revenue of $70.28 million for the quarter, compared to analyst estimates of $65.27 million. During the same period last year, the business posted ($1.25) EPS. Krystal Biotech’s revenue was up 70283900.0% compared to the same quarter last year. On average, equities research analysts predict that Krystal Biotech, Inc. will post 3.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on KRYS shares. Evercore ISI raised their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research note on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. HC Wainwright raised their price objective on shares of Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. Citigroup reiterated a “neutral” rating and issued a $204.00 target price (up previously from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. Finally, Chardan Capital increased their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and a consensus target price of $196.75.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).